S
Svelte Medical Systems
Delivers novel products in the coronary stent market to curb key clinical issues by improving stent deliverability
About Svelte Medical Systems
Svelte Medical Systems, founded in 2007 by the accomplished Fischell family—David, Robert, and Tim—is a privately-held company focused on developing advanced coronary stent systems. The company operates within the health care equipment industry, specifically targeting the challenges of coronary artery disease. Its headquarters are in New Providence, New Jersey.
The business is centered on creating and commercializing highly deliverable balloon-expandable stents. Svelte Medical Systems serves interventional cardiologists and aims to improve patient outcomes while reducing procedural complexity and costs. The company generates revenue through the sale of its specialized medical devices to healthcare providers and hospitals.
A key offering is the SLENDER Integrated Delivery System (IDS), an 'all-in-one' system that combines a guidewire, balloon, and stent. This design streamlines percutaneous coronary interventions (PCI) by eliminating several steps, which can reduce procedure time, radiation exposure, and cost. Another primary product is the DIRECT RX, a rapid-exchange drug-eluting stent (DES) system. Both systems utilize a bioresorbable drug coating which demonstrated a very low 1.5% clinically-driven target lesion revascularization (TLR) at one year in clinical studies. These products are specifically designed to facilitate transradial intervention (TRI), a procedure where access is gained through the wrist, enhancing patient comfort and reducing complications. A significant milestone was achieved in December 2021, when the company received U.S. Food and Drug Administration (FDA) approval to commercialize both the SLENDER IDS and DIRECT RX systems in the United States.
Source: Dealroom company dataNews
Open roles
Svelte Medical Systems in the New Providence ecosystem
The Svelte Medical Systems office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
New Science Ventures
Series B and later2 investors entered at this stage
- AVApjohn ventures
- CLCNF Investments, LLC
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Svelte Medical Systems on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Svelte Medical Systems on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

